InvestorsHub Logo
Followers 2
Posts 160
Boards Moderated 0
Alias Born 01/28/2014

Re: None

Monday, 02/09/2015 11:35:47 AM

Monday, February 09, 2015 11:35:47 AM

Post# of 19

Miraculins Moves Closer To Commercialization

Follow this company

Companies Mentioned
PK:MCUIF / NASDAQ:PODD / TSX.V:MOM
02/09/2015 [ACCESSWIRE]
WHITEFISH, MT / ACCESSWIRE / February 9, 2015 / Diabetes is the seventh leading cause of death in the United States with over a million new cases each year, according to the American Diabetes Association, costing the healthcare system $176 billion in direct costs and the economy $76 billion in lost productivity in 2012.
The metabolic disease is characterized by the body's inability to produce enough insulin, or more commonly, to not be able to effectively use the insulin it does produce, both of which cause elevated and damaging glucose levels in the blood. While companies like Eli Lilly & Co. (NYSE: LLY) and Novo Nordisk A/S (NYSE: NVO) provide artificial insulin to fill the void, there are no cures for diabetes that alleviate a patient's need for costly lifelong treatment. One of the best ways to prevent or slow down the onset of diabetes and its disastrous complications is to make dietary and lifestyle changes that inhibit its formation from the start.
Unfortunately, it's difficult to predict when diabetes is becoming a major risk as you can have it for years without any symptoms while it causes unseen internal damage. Pre-diabetes affects some 86 million Americans over the age of 20 (9 out of 10 are undiagnosed), but the only way to diagnose it is through invasive blood testing. Patients often delay undergoing these tests, which means that the preventable stage of the disease is often ignored and undiagnosed until it's too late and full-blown diabetes is developed requiring lifelong treatment.
The Advantages of a Non-Invasive Test
Miraculins Inc. (TSX-V: MOM) (OTC: MCUIF), a medical device company that acquires, develops and commercializes non-invasive screening tests to aid physicians in the earlier diagnosis of disease, is introducing a non-invasive diabetes screening test that takes just 90 seconds to complete. It has the potential to affect real change by making early diabetes screening easily accessible without requiring needles, blood draw, fasting, or waiting and by creating a tipping point for action, motivating patients at risk to seek medical care and attention before the disease becomes uncontrollable.

http://www.accesswire.com/viewarticle.aspx?id=425706

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.